Ryan Moody, MD
Pulmonary Disease · Savannah, GANPI 1629191853
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Boehringer Ingelheim at 49.6% of the total. 2025 is the largest year on record at $20,143, more than ten times the $1,423 reported in 2019. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $53.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$25K
- Sanofi$9K
- AstraZeneca$2K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $9K from 44 others
What the payments were for
- Consulting fees$6,32413%
- Speaking & faculty fees$23,31046%
- Travel & lodging$1,9084%
- Food & beverage$18,16136%
- Education$6791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,382 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 56 | $710,057 |
| UptraviSelexipag | 35 | $698,945 |
| AdempasRiociguat | 32 | $418,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 489 | $415,997 |
| OfevNintedanib Esylate | 32 | $413,665 |
| Dupixent PenDupilumab | 95 | $398,927 |
| TezspireTezepelumab-Ekko | 43 | $186,223 |
| Fasenra PenBenralizumab | 32 | $179,179 |
| Pirfenidone | 31 | $127,505 |
| Ambrisentan | 39 | $107,752 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 137 | $106,844 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 144 | $84,834 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 134 | $69,545 |
| Breo ElliptaFluticasone/Vilanterol | 158 | $68,993 |
| Spiriva RespimatTiotropium Bromide | 68 | $41,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,760 | $1,409,00291 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,108 | $576,022847 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $24,972 | $549,216262 claims |
| BayerAdempas | $97 | $418,87832 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,194 | $317,543262 claims |
| PfizerEliquis | $60 | $18,21621 claims |
| Johnson & JohnsonXarelto | $55 | $10,69514 claims |
| MerckDulera | $769 | $7,27523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Savannah
- Lawrence McDermottSavannah$963K
- Michael MullinsSavannah$132K
- Michael PerkinsSavannah$67K
- Gifford LorenzSavannah$20K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.